OBJECTIVE. The purpose of this study was to investigate the overall survival, efficacy, and safety of small (100-300 μm) versus large (300-500 and 500-700 μm) doxorubicin drugeluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC). MATERIALS AND METHODS. Ninety-four consecutive patients with unresectable HCC who underwent 269 DEB TACE procedures in 48 months were studied. DEB TACE procedures were performed using different DEB sizes: 100-300 μm (Group A, 59 patients) and with mixed 300-500 and 500-700 μm DEB (Group B, 35 patients). Survival rates were compared between the groups. RESULTS. The overall median survival in groups A and B were 15.1 and 11.1 months, respectively (p = 0.005). Both groups were similar in demographics, tumor burden, and differential staging (p> 0.5). Substratification of overall survival according to Child-Pugh class and Okuda, Cancer of the Liver Italian Program (CLIP), and Barcelona Clinic Liver Cancer (BCLC) staging were significantly higher in group A than in group B (p <0.05). Common terminology criteria for adverse events (CTCAE) grade III adverse events and 30-day mortality were significantly lower in group A than in group B (6.8% vs 20%; p = 0.04, and 0% vs 14.3%; p = 0.001, respectively). The particle size, Child-Pugh class, and serum α-fetoprotein level were significant prognostic indicators of survival on multivariate analysis. CONCLUSION. TACE with 100-300 μm sized DEB is associated with significantly higher survival rate and lower complications than TACE with 300-500 and 500-700 μm sized DEB.
- Doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE)
- Small versus large DEB TACE
- Unresectable hepatocellular carcinoma (HCC)
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging